Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses BDX in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named BDX in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Thomas Polen | $1,395,463 | $0 | $9,991,854 | $3,311,861 | $1,852,010 | $236,700 | $341,251 | $17,129,140 |
| Chairman, Chief Executive Officer and President | ||||||||
| Christopher DelOrefice | 837,500 | 0 | 3,140,481 | 1,040,916 | 722,500 | 0 | 135,767 | 5,877,164 |
| Executive Vice President and Chief Financial Officer | ||||||||
| Michael Feld | 775,000 | 0 | 1,641,596 | 544,118 | 533,588 | 0 | 602,054 | 4,096,356 |
| Executive Vice President, Chief Revenue Officer and President, Life Sciences Segment | ||||||||
| Michael Garrison | 768,750 | 0 | 1,641,596 | 544,118 | 533,588 | 102,800 | 58,188 | 3,649,040 |
| Executive Vice President and President, Medical Essentials and BioPharma Systems Segments | ||||||||
| Richard Byrd | 756,250 | 0 | 1,427,531 | 473,139 | 592,875 | 91,833 | 57,429 | 3,399,056 |
| Executive Vice President and President, Interventional Segment | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Thomas Polen | $17,129,140 | $17,314,606 | $17,309,938 | −185,466 |
| Christopher DelOrefice | 5,877,164 | 5,628,654 | 5,206,390 | +248,510 |
| Michael Feld | 4,096,356 | — | — | — |
| Michael Garrison | 3,649,040 | 3,622,082 | 3,654,368 | +26,958 |
| Richard Byrd | 3,399,056 | 3,268,663 | — | +130,393 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Michael Feld | EVP, CRO & Pres. Life Sciences | 2025-12-26 | D | 74 | $196 | $14,510 | Common | Form 4 ↗ |
| David Shan | EVP and Chief ISC Officer | 2026-01-03 | D | 44 | 0 | 0 | Common | Form 4 ↗ |
| Michael Garrison | EVP & Pres Med.Essntl&BioPharm | 2026-01-15 | D | 2,454 | 209 | 512,886 | Common | Form 4 ↗ |
| Michael Garrison | EVP & Pres Med.Essntl&BioPharm | 2026-01-15 | D | 3,054 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Garrison | EVP & Pres Med.Essntl&BioPharm | 2026-01-15 | D | 1,010 | 207 | 208,605 | Common | Form 4 ↗ |
| Michael Garrison | EVP & Pres Med.Essntl&BioPharm | 2026-01-15 | D | 600 | 209 | 125,400 | Common | Form 4 ↗ |
| Michael Garrison | EVP & Pres Med.Essntl&BioPharm | 2026-01-15 | A | 3,054 | 168 | 512,797 | Common | Form 4 ↗ |
| Pamela L. Spikner | SVP Controller & CAO | 2026-01-21 | D | 84 | 0 | 0 | Common | Form 4 ↗ |
| Michael Feld | EVP, CRO & Pres. Life Sciences | 2026-01-26 | D | 75 | 203 | 15,205 | Common | Form 4 ↗ |
| Jeffrey W. Henderson | Director | 2026-01-27 | A | 1,098 | 0 | 0 | Common | Form 4 ↗ |
| Jacqueline Wright | Director | 2026-01-27 | A | 1,098 | 0 | 0 | Common | Form 4 ↗ |
| Bertram L. Scott | Director | 2026-01-27 | A | 1,098 | 0 | 0 | Common | Form 4 ↗ |
| Joanne Waldstreicher | Director | 2026-01-27 | A | 1,098 | 0 | 0 | Common | Form 4 ↗ |
| William M. Brown | Director | 2026-01-27 | A | 1,098 | 0 | 0 | Common | Form 4 ↗ |
| Christopher Jones | Director | 2026-01-27 | A | 1,098 | 0 | 0 | Common | Form 4 ↗ |
| Robert L. Huffines | Director | 2026-01-27 | A | 1,098 | 0 | 0 | Common | Form 4 ↗ |
| Gregory J. Hayes | Director | 2026-01-27 | A | 1,098 | 0 | 0 | Common | Form 4 ↗ |
| Carrie L. Byington | Director | 2026-01-27 | A | 1,098 | 0 | 0 | Common | Form 4 ↗ |
| R. Andrew Eckert | Director | 2026-01-27 | A | 1,098 | 0 | 0 | Common | Form 4 ↗ |
| Timothy M. Ring | Director | 2026-01-27 | A | 1,098 | 0 | 0 | Common | Form 4 ↗ |
| Robert L. Huffines | Director | 2026-02-04 | A | 100 | 202 | 20,191 | Derivative, Class A Common | Form 4 ↗ |
| Christopher Jones | Director | 2026-02-04 | A | 272 | 202 | 54,920 | Derivative, Class A Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-02-04 | — | 30 | — | ~6,057 | 1 insider, 1 accrual row | ||
| BECTON DICKINSON & CO | Greater-than-10% holder | 2026-02-09 | D | 284,771,350 | — | — | Common | Form 4 ↗ |
| Bertram L. Scott | Director | 2026-02-18 | D | 953 | 183 | 174,027 | Common | Form 4 ↗ |
| Michael Feld | EVP, Chief Revenue Officer | 2026-02-26 | D | 75 | 182 | 13,638 | Common | Form 4 ↗ |
| Pamela L. Spikner | SVP Controller & CAO | 2026-03-02 | A | 931 | 0 | 0 | Common | Form 4 ↗ |
| Vitor Roque | Interim CFO | 2026-03-02 | A | 931 | 0 | 0 | Common | Form 4 ↗ |
| Lanesha Minnix | EVP and General Counsel | 2026-03-16 | A | 7,492 | 0 | 0 | Common | Form 4 ↗ |
| Michael Feld | EVP, Chief Revenue Officer | 2026-03-26 | D | 75 | 157 | 11,762 | Common | Form 4 ↗ |
| Shana Carol Neal | EVP and Chief People Officer | 2026-04-06 | D | 1,146 | 0 | 0 | Common | Form 4 ↗ |
| Michael Feld | EVP, Chief Revenue Officer | 2026-04-27 | D | 74 | 152 | 11,244 | Common | Form 4 ↗ |
| Vitor Roque | EVP & Chief Financial Officer | 2026-05-07 | A | 1,721 | 0 | 0 | Common | Form 4 ↗ |
| Carrie L. Byington | Director | 2026-05-08 | A | 105 | 149 | 15,649 | Derivative, Class A Common | Form 4 ↗ |
| Robert L. Huffines | Director | 2026-05-08 | A | 210 | 149 | 31,298 | Derivative, Class A Common | Form 4 ↗ |
| Michael Feld | EVP, Chief Revenue Officer | 2026-05-26 | D | 75 | 147 | 11,051 | Common | Form 4 ↗ |
| Thomas E. Polen Jr | Director | 2026-06-01 | D | 2,764 | 146 | 404,511 | Common, open-market sale | Form 4 ↗ |
| Thomas E. Polen Jr | Director | 2026-06-01 | D | 17,445 | 146 | 2,549,587 | Common | Form 4 ↗ |
| Peter Menziuso | EVP and President, BDI | 2026-06-01 | A | 14,258 | 0 | 0 | Common | Form 4 ↗ |
| Thomas E. Polen Jr | Director | 2026-06-01 | A | 20,209 | 126 | 2,549,567 | Common | Form 4 ↗ |
| Thomas E. Polen Jr | Director | 2026-06-01 | D | 20,209 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Garrison | EVP & Pres Med.Essntl&BioPharm | 2026-06-10 | D | 1,100 | 151 | 166,628 | Common | Form 4 ↗ |
| Michael Garrison | EVP & Pres Med.Essntl&BioPharm | 2026-06-24 | D | 1,100 | 146 | 160,226 | Common | Form 4 ↗ |
| Michael Feld | EVP, Chief Revenue Officer | 2026-06-26 | D | 75 | 153 | 11,460 | Common | Form 4 ↗ |
| Bilal Muhsin | EVP & President Connected Care | 2026-07-01 | D | 1,935 | 0 | 0 | Common | Form 4 ↗ |
| Bilal Muhsin | EVP & President Connected Care | 2026-07-01 | A | 14,342 | 0 | 0 | Common | Form 4 ↗ |
| Michael Feld | EVP, Chief Revenue Officer | 2026-07-27 | D | 75 | 157 | 11,785 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Michael Feld | EVP, CRO & Pres. Life Sciences | 2025-12-26 | D | 74 | $196 | $14,510 | Common | Form 4 ↗ |
| David Shan | EVP and Chief ISC Officer | 2026-01-03 | D | 44 | 0 | 0 | Common | Form 4 ↗ |
| Michael Garrison | EVP & Pres Med.Essntl&BioPharm | 2026-01-15 | D | 2,454 | 209 | 512,886 | Common | Form 4 ↗ |
| Michael Garrison | EVP & Pres Med.Essntl&BioPharm | 2026-01-15 | D | 3,054 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Garrison | EVP & Pres Med.Essntl&BioPharm | 2026-01-15 | D | 1,010 | 207 | 208,605 | Common | Form 4 ↗ |
| Michael Garrison | EVP & Pres Med.Essntl&BioPharm | 2026-01-15 | D | 600 | 209 | 125,400 | Common | Form 4 ↗ |
| Michael Garrison | EVP & Pres Med.Essntl&BioPharm | 2026-01-15 | A | 3,054 | 168 | 512,797 | Common | Form 4 ↗ |
| Pamela L. Spikner | SVP Controller & CAO | 2026-01-21 | D | 84 | 0 | 0 | Common | Form 4 ↗ |
| Michael Feld | EVP, CRO & Pres. Life Sciences | 2026-01-26 | D | 75 | 203 | 15,205 | Common | Form 4 ↗ |
| Jeffrey W. Henderson | Director | 2026-01-27 | A | 1,098 | 0 | 0 | Common | Form 4 ↗ |
| Jacqueline Wright | Director | 2026-01-27 | A | 1,098 | 0 | 0 | Common | Form 4 ↗ |
| Bertram L. Scott | Director | 2026-01-27 | A | 1,098 | 0 | 0 | Common | Form 4 ↗ |
| Joanne Waldstreicher | Director | 2026-01-27 | A | 1,098 | 0 | 0 | Common | Form 4 ↗ |
| William M. Brown | Director | 2026-01-27 | A | 1,098 | 0 | 0 | Common | Form 4 ↗ |
| Christopher Jones | Director | 2026-01-27 | A | 1,098 | 0 | 0 | Common | Form 4 ↗ |
| Robert L. Huffines | Director | 2026-01-27 | A | 1,098 | 0 | 0 | Common | Form 4 ↗ |
| Gregory J. Hayes | Director | 2026-01-27 | A | 1,098 | 0 | 0 | Common | Form 4 ↗ |
| Carrie L. Byington | Director | 2026-01-27 | A | 1,098 | 0 | 0 | Common | Form 4 ↗ |
| R. Andrew Eckert | Director | 2026-01-27 | A | 1,098 | 0 | 0 | Common | Form 4 ↗ |
| Timothy M. Ring | Director | 2026-01-27 | A | 1,098 | 0 | 0 | Common | Form 4 ↗ |
| Robert L. Huffines | Director | 2026-02-04 | A | 100 | 202 | 20,191 | Derivative, Class A Common | Form 4 ↗ |
| Christopher Jones | Director | 2026-02-04 | A | 272 | 202 | 54,920 | Derivative, Class A Common | Form 4 ↗ |
| Carrie L. Byington | Director | 2026-02-04 | A | 30 | 202 | 6,057 | Derivative, Class A Common | Form 4 ↗ |
| BECTON DICKINSON & CO | Greater-than-10% holder | 2026-02-09 | D | 284,771,350 | — | — | Common | Form 4 ↗ |
| Bertram L. Scott | Director | 2026-02-18 | D | 953 | 183 | 174,027 | Common | Form 4 ↗ |
| Michael Feld | EVP, Chief Revenue Officer | 2026-02-26 | D | 75 | 182 | 13,638 | Common | Form 4 ↗ |
| Pamela L. Spikner | SVP Controller & CAO | 2026-03-02 | A | 931 | 0 | 0 | Common | Form 4 ↗ |
| Vitor Roque | Interim CFO | 2026-03-02 | A | 931 | 0 | 0 | Common | Form 4 ↗ |
| Lanesha Minnix | EVP and General Counsel | 2026-03-16 | A | 7,492 | 0 | 0 | Common | Form 4 ↗ |
| Michael Feld | EVP, Chief Revenue Officer | 2026-03-26 | D | 75 | 157 | 11,762 | Common | Form 4 ↗ |
| Shana Carol Neal | EVP and Chief People Officer | 2026-04-06 | D | 1,146 | 0 | 0 | Common | Form 4 ↗ |
| Michael Feld | EVP, Chief Revenue Officer | 2026-04-27 | D | 74 | 152 | 11,244 | Common | Form 4 ↗ |
| Vitor Roque | EVP & Chief Financial Officer | 2026-05-07 | A | 1,721 | 0 | 0 | Common | Form 4 ↗ |
| Carrie L. Byington | Director | 2026-05-08 | A | 105 | 149 | 15,649 | Derivative, Class A Common | Form 4 ↗ |
| Robert L. Huffines | Director | 2026-05-08 | A | 210 | 149 | 31,298 | Derivative, Class A Common | Form 4 ↗ |
| Michael Feld | EVP, Chief Revenue Officer | 2026-05-26 | D | 75 | 147 | 11,051 | Common | Form 4 ↗ |
| Thomas E. Polen Jr | Director | 2026-06-01 | D | 2,764 | 146 | 404,511 | Common, open-market sale | Form 4 ↗ |
| Thomas E. Polen Jr | Director | 2026-06-01 | D | 17,445 | 146 | 2,549,587 | Common | Form 4 ↗ |
| Peter Menziuso | EVP and President, BDI | 2026-06-01 | A | 14,258 | 0 | 0 | Common | Form 4 ↗ |
| Thomas E. Polen Jr | Director | 2026-06-01 | A | 20,209 | 126 | 2,549,567 | Common | Form 4 ↗ |
| Thomas E. Polen Jr | Director | 2026-06-01 | D | 20,209 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Garrison | EVP & Pres Med.Essntl&BioPharm | 2026-06-10 | D | 1,100 | 151 | 166,628 | Common | Form 4 ↗ |
| Michael Garrison | EVP & Pres Med.Essntl&BioPharm | 2026-06-24 | D | 1,100 | 146 | 160,226 | Common | Form 4 ↗ |
| Michael Feld | EVP, Chief Revenue Officer | 2026-06-26 | D | 75 | 153 | 11,460 | Common | Form 4 ↗ |
| Bilal Muhsin | EVP & President Connected Care | 2026-07-01 | D | 1,935 | 0 | 0 | Common | Form 4 ↗ |
| Bilal Muhsin | EVP & President Connected Care | 2026-07-01 | A | 14,342 | 0 | 0 | Common | Form 4 ↗ |
| Michael Feld | EVP, Chief Revenue Officer | 2026-07-27 | D | 75 | 157 | 11,785 | Common | Form 4 ↗ |
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Richard Byrd | RSU | — | — | — | 2,220 | — | $479,542 |
| Michael Garrison | OPTION | — | — | — | 10,004 | — | 544,118 |
| Michael Feld | PSU | — | 2,543 | 5,085 | — | 10,170 | 1,090,122 |
| Michael Garrison | PSU | — | 2,543 | 5,085 | — | 10,170 | 1,090,122 |
| Richard Byrd | OPTION | — | — | — | 8,699 | — | 473,139 |
| Michael Feld | OPTION | — | — | — | 10,004 | — | 544,118 |
| Christopher DelOrefice | OPTION | — | — | — | 19,138 | — | 1,040,916 |
| Thomas Polen | OPTION | — | — | — | 60,891 | — | 3,311,861 |
| Christopher DelOrefice | PSU | — | 4,864 | 9,728 | — | 19,456 | 2,085,489 |
| Michael Garrison | RSU | — | — | — | 2,553 | — | 551,474 |
| Michael Feld | RSU | — | — | — | 2,553 | — | 551,474 |
| Thomas Polen | PSU | — | 15,476 | 30,951 | — | 61,902 | 6,635,275 |
| Christopher DelOrefice | RSU | — | — | — | 4,884 | — | 1,054,993 |
| Richard Byrd | PSU | — | 2,211 | 4,422 | — | 8,844 | 947,988 |
| Thomas Polen | RSU | — | — | — | 15,539 | — | 3,356,579 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Richard Byrd | $479,542 | $947,988 | $473,139 | 49.9% |
| Michael Garrison | 551,474 | 1,090,122 | 544,118 | 49.9% |
| Michael Feld | 551,474 | 1,090,122 | 544,118 | 49.9% |
| Christopher DelOrefice | 1,054,993 | 2,085,489 | 1,040,916 | 49.9% |
| Thomas Polen | 3,356,579 | 6,635,275 | 3,311,861 | 49.9% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Richard Byrd | SAR | 8,699 | 224.25 | — |
| Michael Garrison | RSU | 7,371 | — | 1,379,630 |
| Christopher DelOrefice | RSU | 14,137 | — | 2,646,022 |
| Michael Garrison | SAR | 4,734 | 238.06 | — |
| Thomas Polen | RSU | 49,539 | — | 9,272,215 |
| Christopher DelOrefice | PSU | 36,632 | — | 6,856,411 |
| Michael Feld | PSU | 10,170 | — | 1,903,519 |
| Thomas Polen | SAR | 34,984 | 238.06 | — |
| Richard Byrd | SAR | 3,705 | 238.06 | — |
| Thomas Polen | SAR | 60,891 | 224.25 | — |
| Christopher DelOrefice | SAR | 19,138 | 224.25 | — |
| Thomas Polen | SAR | 19,222 | 241.1 | — |
| Christopher DelOrefice | SAR | 9,330 | 238.06 | — |
| Christopher DelOrefice | SAR | 4,738 | 241.1 | — |
| Richard Byrd | SAR | 1,992 | 241.1 | — |
| Michael Garrison | SAR | 1,992 | 241.1 | — |
| Thomas Polen | PSU | 120,938 | — | 22,635,965 |
| Michael Garrison | PSU | 19,832 | — | 3,711,955 |
| Richard Byrd | PSU | 16,358 | — | 3,061,727 |
| Richard Byrd | RSU | 5,985 | — | 1,120,212 |
| Thomas Polen | SAR | 47,502 | 238.89 | — |
| Michael Feld | RSU | 6,976 | — | 1,305,698 |
| Christopher DelOrefice | SAR | 13,819 | 238.89 | — |
| Richard Byrd | SAR | 6,046 | 238.89 | — |
| Michael Garrison | SAR | 7,773 | 238.89 | — |
| Michael Feld | SAR | 10,004 | 224.25 | — |
| Michael Garrison | SAR | 10,004 | 224.25 | — |
Our goal is to provide an executive compensation program that best serves the long-term interests of our shareholders. We believe that attracting and retaining superior talent and rewarding performance is key to delivering long-term shareholder returns, and that a competitive compensation program is critical to that end.
| CEO STI target (% of salary) | 156% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Semler Brossy |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-01-27 | 219,718,308 | 20,659,474 | 1,176,517 | 91.41% | Passed |
| 2025 | 2025-01-28 | 208,413,830 | 25,696,707 | 622,784 | 89.02% | Passed |
| 2024 | 2024-01-23 | 220,789,127 | 17,666,312 | 1,650,510 | 92.59% | Passed |
| 2023 | 2023-01-24 | 218,048,059 | 16,612,567 | 773,923 | 92.92% | Passed |
| 2022 | 2022-01-25 | 182,848,043 | 48,903,644 | 573,457 | 78.9% | Passed |
| 2021 | 2021-01-26 | 155,094,897 | 76,265,280 | 1,138,722 | 67.04% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-01-27 | 91.41%a |
| 2025 | 2025-01-28 | 89.02%b |
| 2024 | 2024-01-23 | 92.59%c |
a. Approved under the standard stated in the filing — “Under New Jersey law, abstentions and broker non-votes will not be counted as votes cast, and, accordingly, will have no effect on the outcome of the vote on these proposals.”.
b. Approved under the standard stated in the filing — “Under New Jersey law, abstentions and broker non-votes will not be counted as votes cast, and, accordingly, will have no effect on the outcome of the vote on these proposals.”.
c. Approved under the standard stated in the filing — “Under New Jersey law, abstentions and broker non-votes will not be counted as votes cast, and, accordingly, will have no effect on the outcome of the vote on these proposals.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 374 : 1 |
|---|---|
| CEO total compensation | $17,129,140 |
| Median employee compensation | $45,831 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Bertram L. ScottIndependent · Lead Independent Director · Compensation and Human Capital · Quality and Regulatory | $160,000 | $215,172 | $0 | $0 | $0 | $375,172 |
| Christopher JonesIndependent · Audit · Corporate Governance and Nominating (Chair) | 145,000 | 215,172 | 0 | 0 | 5,000 | 365,172 |
| R. Andrew EckertIndependent · Audit · Compensation and Human Capital (Chair) | 145,000 | 215,172 | 0 | 0 | 5,000 | 365,172 |
| Catherine M. BurzikIndependent · Corporate Governance and Nominating · Quality and Regulatory (Chair) · Not standing for re-election | 145,000 | 215,172 | 0 | 0 | 0 | 360,172 |
| Jeffrey W. HendersonIndependent · Audit (Chair) · Compensation and Human Capital | 145,000 | 215,172 | 0 | 0 | 0 | 360,172 |
| Carrie L. ByingtonIndependent · Audit · Quality and Regulatory | 120,000 | 215,172 | 0 | 0 | 10,000 | 345,172 |
| Claire M. FraserIndependent · Compensation and Human Capital · Corporate Governance and Nominating | 120,000 | 215,172 | 0 | 0 | 9,500 | 344,672 |
| Joanne WaldstreicherIndependent · Corporate Governance and Nominating · Quality and Regulatory | 120,000 | 215,172 | 0 | 0 | 1,000 | 336,172 |
| Timothy M. RingIndependent · Audit · Quality and Regulatory | 120,000 | 215,172 | 0 | 0 | 0 | 335,172 |
| William M. BrownIndependent · Compensation and Human Capital · Corporate Governance and Nominating | 120,000 | 215,172 | 0 | 0 | 0 | 335,172 |
| Gregory J. HayesIndependent · Audit · Compensation and Human Capital · Newly elected | 42,125 | 181,329 | 0 | 0 | 0 | 223,454 |
| Jacqueline WrightIndependent · Audit · Compensation and Human Capital · Newly elected | 0 | 0 | 0 | 0 | 0 | 0 |
| Robert L. HuffinesIndependent · Audit · Corporate Governance and Nominating · Newly elected | 0 | 0 | 0 | 0 | 0 | 0 |
| Thomas E. PolenEmployee director · Board Chair | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $120,000 |
|---|---|
| Annual equity retainer | $215,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | — |
| Stock ownership guideline | 5x annual cash retainer ($600,000) |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $1,382,125 |
| Equity awards (grant-date value) | $2,333,049 |
| All other compensation | $30,500 |
| Total cost of the board | $3,745,674 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Becton Dickinson & Co names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Becton Dickinson & Co.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific Inc. | 2025 | Marc Casper | $1,785,534 | $65,730,211 | $7,951,377 | $3,742,123 | $79,923,350 |
| 2 | Baxter International Inc. | 2025 | Andrew Hider | 499,315 | 23,133,518 | 3,185,053 | 820,125 | 29,805,182 |
| 3 | Abbott Laboratories | 2025 | Robert Ford | 1,500,000 | 8,787,378 | 8,788,430 | 1,968,750 | 24,198,660 |
| 4 | Danaher Corporation | 2025 | Rainer Blair | 1,400,000 | 9,292,370 | 8,386,657 | 4,194,400 | 23,795,280 |
| 5 | Boston Scientific Corporation | 2025 | Michael Mahoney | 1,442,603 | 13,608,056 | 3,749,980 | 4,002,001 | 23,532,050 |
| 6 | Medtronic plc | 2026 | Geoffrey Martha | 1,399,039 | 13,672,200 | 5,175,559 | 2,307,200 | 22,940,252 |
| 7 | Stryker Corporation | 2025 | Kevin Lobo | 1,500,000 | 16,684,917 | 0 | 2,250,000 | 21,401,495 |
| 8 | GE Healthcare Technologies, Inc. | 2025 | Peter Arduini | 1,324,983 | 11,249,533 | 3,624,970 | 2,081,084 | 18,562,794 |
| 9 | Becton Dickinson & Co | 2025 | Thomas Polen | 1,395,463 | 9,991,854 | 3,311,861 | 1,852,010 | 17,129,140 |
| 10 | Zimmer Biomet Holdings, Inc. | 2025 | Ivan Tornos | 1,281,846 | 12,000,101 | 0 | 2,420,767 | 16,106,550 |
| 11 | Agilent Technologies, Inc. | 2025 | Padraig McDonnell | 1,141,345 | 8,169,850 | 2,017,759 | 1,436,809 | 12,827,236 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Becton Dickinson & Co | 85% | PSU 50 · Options 25 · RSU 25 | No | Semler Brossy |
| Abbott Laboratories | 75.0% | Options 50 · PSU 50 | No | Meridian Compensation Partners, LLC |
| Agilent Technologies, Inc. | not disclosed | PSU 60 · Options 20 · RSU 20 | No | Semler Brossy |
| Baxter International Inc. | not disclosed | PSU 50 · Stock Options 25 · RSU 25 | not disclosed | Aon |
| Boston Scientific Corporation | 173% | PSU 50 · RSU 25 · Options 25 | No | Semler Brossy Consulting Group, LLC |
| Danaher Corporation | not disclosed | Options 50 · RSU 50 | not disclosed | FW Cook |
| GE Healthcare Technologies, Inc. | 101% | PSU 50 · Options 25 · RSU 25 | No | Semler Brossy |
| Medtronic plc | 103% | PSU 50 · Options 30 · RSU 20 | No | Semler Brossy |
| Stryker Corporation | 100% | PSU 48 · Options 34 | No | Semler Brossy |
| Thermo Fisher Scientific Inc. | 99.8% | PSU 50 · Options 50 | Yes — Relative TSR | Pearl Meyer |
| Zimmer Biomet Holdings, Inc. | 125.9% | RSU 50 · PSU 50 | Yes — Relative TSR | Semler Brossy |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Thomas Polen | DEF 14A | 2025-12-18 | 0001628280-25-057846 | Section “Fiscal year 2025 summary compensation table”. As printed: 17,129,140. Filing ↗machine: r2 · c27 · span 1173285–1173295 |
| 2 | Section 01, Christopher DelOrefice | DEF 14A | 2025-12-18 | 0001628280-25-057846 | Section “Fiscal year 2025 summary compensation table”. As printed: 5,877,164. Filing ↗machine: r5 · c27 · span 1183378–1183387 |
| 3 | Section 01, Michael Feld | DEF 14A | 2025-12-18 | 0001628280-25-057846 | Section “Fiscal year 2025 summary compensation table”. As printed: 4,096,356. Filing ↗machine: r10 · c27 · span 1200214–1200223 |
| 4 | Section 01, Michael Garrison | DEF 14A | 2025-12-18 | 0001628280-25-057846 | Section “Fiscal year 2025 summary compensation table”. As printed: 3,649,040. Filing ↗machine: r11 · c27 · span 1204119–1204128 |
| 5 | Section 01, Richard Byrd | DEF 14A | 2025-12-18 | 0001628280-25-057846 | Section “Fiscal year 2025 summary compensation table”. As printed: 3,399,056. Filing ↗machine: r8 · c27 · span 1193413–1193422 |
| 6 | Section 03, Richard Byrd RSU | DEF 14A | 2025-12-18 | 0001628280-25-057846 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗ |
| 7 | Section 03, Michael Garrison OPTION | DEF 14A | 2025-12-18 | 0001628280-25-057846 | Section “THE BOARD OF DIRECTORS RECOMMENDSVOTE &” · grants of plan-based awards table. Filing ↗machine: t174 · r11 · c8 · span 1202728–1202735 |
| 8 | Section 03, Michael Feld PSU | DEF 14A | 2025-12-18 | 0001628280-25-057846 | Section “THE BOARD OF DIRECTORS RECOMMENDSVOTE &” · grants of plan-based awards table. Filing ↗machine: t175 · r5 · c1 · span 1218779–1218788 |
| 9 | Section 03, Michael Garrison PSU | DEF 14A | 2025-12-18 | 0001628280-25-057846 | Section “THE BOARD OF DIRECTORS RECOMMENDSVOTE &” · grants of plan-based awards table. Filing ↗machine: t175 · r6 · c1 · span 1219800–1219809 |
| 10 | Section 03, Richard Byrd OPTION | DEF 14A | 2025-12-18 | 0001628280-25-057846 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t170 · r4 · c9 · span 1151353–1151360 |
| 11 | Section 03, Michael Feld OPTION | DEF 14A | 2025-12-18 | 0001628280-25-057846 | Section “THE BOARD OF DIRECTORS RECOMMENDSVOTE &” · grants of plan-based awards table. Filing ↗machine: t174 · r10 · c8 · span 1198828–1198835 |
| 12 | Section 03, Christopher DelOrefice OPTION | DEF 14A | 2025-12-18 | 0001628280-25-057846 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t170 · r3 · c9 · span 1148178–1148187 |
| 13 | Section 03, Thomas Polen OPTION | DEF 14A | 2025-12-18 | 0001628280-25-057846 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t170 · r2 · c9 · span 1144987–1144996 |
| 14 | Section 03, Christopher DelOrefice PSU | DEF 14A | 2025-12-18 | 0001628280-25-057846 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t175 · r3 · c1 · span 1216875–1216884 |
| 15 | Section 03, Michael Garrison RSU | DEF 14A | — | 0001628280-25-057846 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗ |
| 16 | Section 03, Michael Feld RSU | DEF 14A | — | 0001628280-25-057846 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗ |
| 17 | Section 03, Thomas Polen PSU | DEF 14A | 2025-12-18 | 0001628280-25-057846 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t175 · r2 · c1 · span 1215917–1215926 |
| 18 | Section 03, Christopher DelOrefice RSU | DEF 14A | 2025-12-18 | 0001628280-25-057846 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗ |
| 19 | Section 03, Richard Byrd PSU | DEF 14A | 2025-12-18 | 0001628280-25-057846 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t175 · r4 · c1 · span 1217828–1217835 |
| 20 | Section 03, Thomas Polen RSU | DEF 14A | 2025-12-18 | 0001628280-25-057846 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗ |
| 21 | Section 07, pay ratio | DEF 14A | 2025-12-18 | 0001628280-25-057846 | Section “CEO Pay Ratio”. As printed: 374 : 1. Filing ↗machine: span 1525421–1525429 |
| 22 | Section 08, Bertram L. Scott | DEF 14A | 2025-12-18 | 0001628280-25-057846 | Section “Director Compensation”. As printed: 375,172. Filing ↗machine: t109 · r12 · c7 · span 765302–765309 |
| 23 | Section 08, Christopher Jones | DEF 14A | 2025-12-18 | 0001628280-25-057846 | Section “Director Compensation”. As printed: 365,172. Filing ↗machine: t109 · r10 · c7 · span 761925–761932 |
| 24 | Section 08, R. Andrew Eckert | DEF 14A | 2025-12-18 | 0001628280-25-057846 | Section “Director Compensation”. As printed: 365,172. Filing ↗machine: t109 · r5 · c7 · span 752584–752591 |
| 25 | Section 08, Catherine M. Burzik | DEF 14A | 2025-12-18 | 0001628280-25-057846 | Section “Director Compensation”. As printed: 360,172. Filing ↗machine: t109 · r3 · c7 · span 749128–749135 |
| 26 | Section 08, Jeffrey W. Henderson | DEF 14A | 2025-12-18 | 0001628280-25-057846 | Section “Director Compensation”. As printed: 360,172. Filing ↗machine: t109 · r8 · c7 · span 758199–758206 |
| 27 | Section 08, Carrie L. Byington | DEF 14A | 2025-12-18 | 0001628280-25-057846 | Section “Director Compensation”. As printed: 345,172. Filing ↗machine: t109 · r4 · c7 · span 750866–750873 |
| 28 | Section 08, Claire M. Fraser | DEF 14A | 2025-12-18 | 0001628280-25-057846 | Section “Director Compensation”. As printed: 344,672. Filing ↗machine: t109 · r6 · c7 · span 754384–754391 |
| 29 | Section 08, Joanne Waldstreicher | DEF 14A | 2025-12-18 | 0001628280-25-057846 | Section “Director Compensation”. As printed: 336,172. Filing ↗machine: t109 · r13 · c7 · span 767055–767062 |
| 30 | Section 08, Timothy M. Ring | DEF 14A | 2025-12-18 | 0001628280-25-057846 | Section “Director Compensation”. As printed: 335,172. Filing ↗machine: t109 · r11 · c7 · span 763638–763645 |
| 31 | Section 08, William M. Brown | DEF 14A | 2025-12-18 | 0001628280-25-057846 | Section “Director Compensation”. As printed: 335,172. Filing ↗machine: t109 · r2 · c7 · span 747229–747236 |
| 32 | Section 08, Gregory J. Hayes | DEF 14A | 2025-12-18 | 0001628280-25-057846 | Section “Director Compensation”. As printed: 223,454. Filing ↗machine: t109 · r7 · c7 · span 756381–756388 |
| 33 | Section 08, Jacqueline Wright | DEF 14A | 2025-12-18 | 0001628280-25-057846 | Section “Director Compensation”. As printed: 0. Filing ↗machine: t109 · r14 · c7 · span 769240–769241 |
| 34 | Section 08, Robert L. Huffines | DEF 14A | 2025-12-18 | 0001628280-25-057846 | Section “Director Compensation”. As printed: 0. Filing ↗machine: t109 · r9 · c7 · span 760129–760130 |
| 35 | Section 08, Thomas E. Polen | DEF 14A | 2025-12-18 | 0001628280-25-057846 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 36 | Section 02, Michael Feld 2025-12-26 | Form 4 | 2025-12-29 | 0001628280-25-058843 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, David Shan 2026-01-03 | Form 4 | 2026-01-06 | 0001963048-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Michael Garrison 2026-01-15 | Form 4 | 2026-01-16 | 0001944816-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Michael Garrison 2026-01-15 | Form 4 | 2026-01-16 | 0001944816-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Michael Garrison 2026-01-15 | Form 4 | 2026-01-16 | 0001944816-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Michael Garrison 2026-01-15 | Form 4 | 2026-01-16 | 0001944816-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Michael Garrison 2026-01-15 | Form 4 | 2026-01-16 | 0001944816-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Pamela L. Spikner 2026-01-21 | Form 4 | 2026-01-23 | 0002012329-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Michael Feld 2026-01-26 | Form 4 | 2026-01-28 | 0001628280-26-003734 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Jeffrey W. Henderson 2026-01-27 | Form 4 | 2026-01-29 | 0001628280-26-004019 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Jacqueline Wright 2026-01-27 | Form 4 | 2026-01-29 | 0001628280-26-003997 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Bertram L. Scott 2026-01-27 | Form 4 | 2026-01-29 | 0001628280-26-004002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Joanne Waldstreicher 2026-01-27 | Form 4 | 2026-01-29 | 0001628280-26-003999 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, William M. Brown 2026-01-27 | Form 4 | 2026-01-29 | 0001628280-26-004010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Christopher Jones 2026-01-27 | Form 4 | 2026-01-29 | 0001628280-26-004006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, Robert L. Huffines 2026-01-27 | Form 4 | 2026-01-29 | 0001628280-26-004008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, Gregory J. Hayes 2026-01-27 | Form 4 | 2026-01-29 | 0001628280-26-004013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Carrie L. Byington 2026-01-27 | Form 4 | 2026-01-29 | 0001628280-26-004015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, R. Andrew Eckert 2026-01-27 | Form 4 | 2026-01-29 | 0001628280-26-004017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, Timothy M. Ring 2026-01-27 | Form 4 | 2026-01-29 | 0001628280-26-004004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, Robert L. Huffines 2026-02-04 | Form 4 | 2026-02-05 | 0001628280-26-005700 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, Christopher Jones 2026-02-04 | Form 4 | 2026-02-05 | 0001628280-26-005690 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 02, Carrie L. Byington 2026-02-04 | Form 4 | 2026-02-05 | 0001628280-26-005695 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 59 | Section 02, BECTON DICKINSON & CO 2026-02-09 | Form 4 | 2026-02-11 | 0001193125-26-046606 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 60 | Section 02, Bertram L. Scott 2026-02-18 | Form 4 | 2026-02-18 | 0001628280-26-009242 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 61 | Section 02, Michael Feld 2026-02-26 | Form 4 | 2026-02-27 | 0001628280-26-012955 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 62 | Section 02, Pamela L. Spikner 2026-03-02 | Form 4 | 2026-03-04 | 0001628280-26-014438 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 63 | Section 02, Vitor Roque 2026-03-02 | Form 4 | 2026-03-04 | 0001628280-26-014440 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 64 | Section 02, Lanesha Minnix 2026-03-16 | Form 4 | 2026-03-17 | 0001628280-26-018607 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 65 | Section 02, Michael Feld 2026-03-26 | Form 4 | 2026-03-27 | 0001628280-26-021644 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 66 | Section 02, Shana Carol Neal 2026-04-06 | Form 4 | 2026-04-06 | 0001628280-26-023944 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 67 | Section 02, Michael Feld 2026-04-27 | Form 4 | 2026-04-28 | 0001628280-26-027731 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 68 | Section 02, Vitor Roque 2026-05-07 | Form 4 | 2026-05-08 | 0001628280-26-032999 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 69 | Section 02, Carrie L. Byington 2026-05-08 | Form 4 | 2026-05-08 | 0001628280-26-033022 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 70 | Section 02, Robert L. Huffines 2026-05-08 | Form 4 | 2026-05-08 | 0001628280-26-033027 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 71 | Section 02, Michael Feld 2026-05-26 | Form 4 | 2026-05-27 | 0001628280-26-038382 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 72 | Section 02, Thomas E. Polen Jr 2026-06-01 | Form 4 | 2026-06-03 | 0001628280-26-040095 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 73 | Section 02, Thomas E. Polen Jr 2026-06-01 | Form 4 | 2026-06-03 | 0001628280-26-040095 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 74 | Section 02, Peter Menziuso 2026-06-01 | Form 4 | 2026-06-02 | 0001628280-26-039738 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 75 | Section 02, Thomas E. Polen Jr 2026-06-01 | Form 4 | 2026-06-03 | 0001628280-26-040095 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 76 | Section 02, Thomas E. Polen Jr 2026-06-01 | Form 4 | 2026-06-03 | 0001628280-26-040095 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 77 | Section 02, Michael Garrison 2026-06-10 | Form 4 | 2026-06-11 | 0001628280-26-042571 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 78 | Section 02, Michael Garrison 2026-06-24 | Form 4 | 2026-06-25 | 0001628280-26-045374 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 79 | Section 02, Michael Feld 2026-06-26 | Form 4 | 2026-06-26 | 0001628280-26-045864 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 80 | Section 02, Bilal Muhsin 2026-07-01 | Form 4 | 2026-07-06 | 0001628280-26-047193 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 81 | Section 02, Bilal Muhsin 2026-07-01 | Form 4 | 2026-07-06 | 0001628280-26-047193 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 82 | Section 02, Michael Feld 2026-07-27 | Form 4 | 2026-07-28 | 0001628280-26-049989 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 83 | Section 06, 2026 vote | Form 8-K | 2026-01-30 | 0001628280-26-004393 | Item 5.07 · say-on-pay result. As reported: 91.41% (votes for as printed: 219,718,308). Filing ↗ |
| 84 | Section 06, 2025 vote | Form 8-K | 2025-01-31 | 0000010795-25-000011 | Item 5.07 · say-on-pay result. As reported: 89.02% (votes for as printed: 208,413,830). Filing ↗ |
| 85 | Section 06, 2024 vote | Form 8-K | 2024-01-26 | 0000010795-24-000006 | Item 5.07 · say-on-pay result. As reported: 92.59% (votes for as printed: 220,789,127). Filing ↗ |
| 86 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 87 | Section 03b vehicle mix (computed) | Computed | — | computed | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 88 | Section 09b board cost (computed) | Computed | — | computed | Cash 1,382,125 + equity 2,333,049 + all other 30,500 = 3,745,674, summed across the director compensation table rows.machine: formula: Σ = 3,745,674 |
| 89 | Thermo Fisher Scientific Inc., Section 10b CEO total | DEF 14A | 2026-04-07 | 0001193125-26-144585 | CEO total compensation as printed in Thermo Fisher Scientific Inc.'s own proxy. As printed: 79,923,350. Filing ↗machine: span 973487–973497 |
| 90 | Baxter International Inc., Section 10b CEO total | DEF 14A | 2026-03-23 | 0001628280-26-020330 | CEO total compensation as printed in Baxter International Inc.'s own proxy. As printed: 29,805,182. Filing ↗machine: r4 · c30 · span 1451066–1451076 |
| 91 | Abbott Laboratories, Section 10b CEO total | DEF 14A | 2026-03-13 | 0001308179-26-000064 | CEO total compensation as printed in Abbott Laboratories's own proxy. As printed: 24,198,660. Filing ↗machine: span 1245488–1245498 |
| 92 | Danaher Corporation, Section 10b CEO total | DEF 14A | 2026-03-25 | 0000313616-26-000101 | CEO total compensation as printed in Danaher Corporation's own proxy. As printed: 23,795,280. Filing ↗machine: t122 · r2 · c21 · span 1070180–1070190 |
| 93 | Boston Scientific Corporation, Section 10b CEO total | DEF 14A | 2026-03-18 | 0000885725-26-000025 | CEO total compensation as printed in Boston Scientific Corporation's own proxy. As printed: 23,532,050. Filing ↗machine: r2 · c27 · span 1249807–1249817 |
| 94 | Medtronic plc, Section 10b CEO total | DEF 14A | 2026-08-17 | 0001613103-26-000010 | CEO total compensation as printed in Medtronic plc's own proxy. As printed: 22,940,252. Filing ↗machine: span 988220–988230 |
| 95 | Stryker Corporation, Section 10b CEO total | DEF 14A | 2026-03-23 | 0000310764-26-000013 | CEO total compensation as printed in Stryker Corporation's own proxy. As printed: 21,401,495. Filing ↗machine: t101 · r2 · c7 · span 1584979–1584989 |
| 96 | GE Healthcare Technologies, Inc., Section 10b CEO total | DEF 14A | 2026-03-19 | 0001932393-26-000021 | CEO total compensation as printed in GE Healthcare Technologies, Inc.'s own proxy. As printed: 18,562,794. Filing ↗machine: t113 · r3 · c20 · span 924977–924987 |
| 97 | Becton Dickinson & Co (subject), Section 10b CEO total | DEF 14A | 2025-12-18 | 0001628280-25-057846 | CEO total compensation as printed in Becton Dickinson & Co's own proxy. As printed: 17,129,140. Filing ↗machine: r2 · c27 · span 1173285–1173295 |
| 98 | Zimmer Biomet Holdings, Inc., Section 10b CEO total | DEF 14A | 2026-04-01 | 0001193125-26-135661 | CEO total compensation as printed in Zimmer Biomet Holdings, Inc.'s own proxy. As printed: 16,106,550. Filing ↗machine: t111 · r3 · c16 · span 1895785–1895795 |
| 99 | Agilent Technologies, Inc., Section 10b CEO total | DEF 14A | 2026-02-06 | 0001193125-26-040286 | CEO total compensation as printed in Agilent Technologies, Inc.'s own proxy. As printed: 12,827,236. Filing ↗machine: r3 · c29 · span 1450982–1450992 |
| 100 | Section 10a, Zimmer Biomet Holdings, Inc. reciprocity | DEF 14A | — | 0001193125-26-135661 | Zimmer Biomet Holdings, Inc. names Becton Dickinson & Co in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 101 | Section 10a, Danaher Corporation reciprocity | DEF 14A | — | 0000313616-26-000101 | Danaher Corporation names Becton Dickinson & Co in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 102 | Section 10a, Baxter International Inc. reciprocity | DEF 14A | — | 0001628280-26-020330 | Baxter International Inc. names Becton Dickinson & Co in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 103 | Section 10a, Stryker Corporation reciprocity | DEF 14A | — | 0000310764-26-000013 | Stryker Corporation names Becton Dickinson & Co in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 104 | Section 10a, Agilent Technologies, Inc. reciprocity | DEF 14A | — | 0001193125-26-040286 | Agilent Technologies, Inc.'s most recent proxy was read; its disclosed peer group does not include Becton Dickinson & Co. Filing ↗ |
| 105 | Section 10a, Boston Scientific Corporation reciprocity | DEF 14A | — | 0000885725-26-000025 | Boston Scientific Corporation names Becton Dickinson & Co in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 106 | Section 10a, GE Healthcare Technologies, Inc. reciprocity | DEF 14A | — | 0001932393-26-000021 | GE Healthcare Technologies, Inc. names Becton Dickinson & Co in its own disclosed peer group (read from its most recent proxy). Filing ↗ |